New research confirms what many have suspected: medical cannabis does not effectively treat anxiety, post-traumatic stress disorder (PTSD), or depression. Despite its widespread use for these conditions in some U.S. states, two recent studies reveal a lack of rigorous scientific evidence supporting its efficacy. The findings underscore a significant gap between anecdotal use and verifiable medical benefit, raising critical questions about current regulatory practices.
The Evidence Gap: What the Studies Show
Researchers analyzed 54 randomized controlled trials – the gold standard for pharmaceutical testing – spanning from 1980 to 2025. The studies, often involving fewer than 100 participants, found no positive effect of cannabis on anxiety, anorexia nervosa, or psychotic disorders. Notably, no trials specifically tested cannabis for depression, leaving a critical question unanswered, though broader evidence suggests little benefit.
This lack of proof is compounded by the unusual way cannabis has been legalized for medical use. Unlike traditional medications, which require FDA approval based on robust clinical trials, cannabis regulation varies widely by state. Forty states and Washington, D.C., permit medical cannabis, with over a dozen specifically including PTSD as a qualifying condition, while others allow it under vague “debilitating psychiatric conditions” clauses. This means patients are accessing a treatment with no proven benefit, in some cases, against explicit scientific recommendations.
Why This Matters: The Regulatory Disconnect
The current system is “completely backward from how medications are typically brought to market,” says psychologist Tory Spindle of Johns Hopkins. The federal illegality of cannabis forces states to regulate it independently, leaving researchers scrambling to catch up with real-world usage. Studying cannabis also faces significant hurdles due to its Schedule I drug classification, which implies high abuse potential and no accepted medical use.
“We all just want people to be able to access medicines that are both effective and safe for their conditions,” says Jack Wilson of the University of Sydney, who led one of the studies. “Unfortunately, for a lot of people using medical cannabis, I don’t think that is the case.”
Potential Harms: Beyond Ineffectiveness
The studies aren’t just finding a lack of benefit; they suggest cannabis could worsen mental health conditions. Research indicates it may exacerbate mania in bipolar disorder and psychotic symptoms in schizophrenia. This raises serious ethical concerns about prescribing a substance with known risks when no therapeutic advantage exists.
The Bottom Line
The scientific consensus is clear: there is little to no high-quality evidence that cannabis effectively treats anxiety, PTSD, or depression. The current patchwork of state-level regulation has allowed medical cannabis to flourish despite the lack of proof, potentially harming vulnerable patients. Until rigorous research fills the evidence gap, policymakers and healthcare providers should prioritize treatments with established efficacy and safety profiles.
